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Abstract
Background and aims Primary aldosteronism (PA) due to unilateral aldosterone-producing adenoma (APA) is preferentially
treated by unilateral adrenalectomy (ADX), but little is known about the changes in lipid and glucose metabolism that may
occur after ADX.
Methods We studied 19 non-diabetic patients who did not use lipid-lowering drugs with PA due to APA before and
6 months after unilateral ADX. Fasting plasma lipids, lipoprotein subfractions, branched-chain amino acids (BCAA), and
GlycA, a pro-inflammatory glycoprotein biomarker, were measured by nuclear magnetic resonance (NMR) spectroscopy.
The Lipoprotein Insulin Resistance (LP-IR) score, which is based on six lipoprotein variables, was calculated.
Results In all patients, hyperaldosteronism was resolved after ADX. Body mass index and fasting plasma glucose were
unchanged, but HbA1c increased (p= 0.002). Plasma triglycerides, large triglyceride-rich lipoprotein (TRL) cholesterol, and
large TRL particles were increased (p < 0.01), resulting in an increase in TRL size (p= 0.027). High-density lipoprotein size was
decreased (p= 0.015). LP-IR scores (p= 0.001) and total BCAA (p= 0.017) were increased, but GlycA remained unaltered.
Conclusions Based on increases in LP-IR scores and BCAA, which each have been shown to predict new onset type 2
diabetes mellitus independent of conventional risk factors in the general population, this preliminary study suggests that
diabetes risk is not improved but may even be increased after ADX for APA despite remission of PA.
Keywords Adrenalectomy ● Branched-chain amino acids ● Lipoprotein insulin resistance index ● Primary aldosteronism ●
Type 2 diabetes risk
Introduction
Primary aldosteronism (PA) is a well-recognized and rather
frequent cause of secondary hypertension with deleterious
effects on cardiometabolic health including high prevalence
of Type 2 diabetes mellitus (T2D) [1–5]. Besides pro-
inflammatory effects of aldosterone [6, 7], PA is likely to be
associated with yet incompletely understood abnormalities
in lipid and glucose metabolism [5, 8]. The majority of PA
cases are due to either unilateral aldosterone-producing
adenoma (APA) or bilateral adrenal hyperplasia (BAH) [9].
Laparoscopic adrenalectomy (ADX) is the preferred treat-
ment modality for APA, and this procedure may result in
relief of hyperaldosteronism in more than 90% of cases [9].
Clearly, this procedure offers the possibility to study
abnormalities in lipid and glucose metabolism as part of
routine follow-up of such patients.
Remarkably, three recent studies have suggested that the
plasma lipoprotein profile may be worsened 1 year after
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unexpected increase in plasma triglycerides (TG) was
observed in all these studies [10–12]. In one of these stu-
dies, there was a small decrease in fasting plasma glucose
(FPG), without a change in the classification of patients
with impaired glucose tolerance or T2D mellitus [11].
Moreover, in a small group of APA patients, the first phase
insulin response to intravenous glucose was diminished
before treatment and increased after unilateral ADX [12].
On the other hand, we observed a small increase in gly-
cated hemoglobin (HbA1c) after unilateral ADX [5],
although insulin sensitivity, determined by the
hyperinsulinemic-euglycemic clamp technique, did not
significantly change after surgery [12].
During the past few years, nuclear magnetic resonance
(NMR)-based techniques have been developed that allow
for the high-throughput quantification of lipoprotein sub-
fractions, glycosylated proteins, and metabolites such as
branched-chain amino acids (BCAA) [13–15]. Using
NMR, we observed lipoprotein abnormalities, including
lower apolipoprotein B (apoB) and triglyceride-rich lipo-
protein (TRL) concentrations in untreated PA patients
together with higher levels of GlycA, a measure of
inflammatory glycoproteins [7]. With this NMR method,
the Lipoprotein Insulin Resistance (LP-IR) score has been
developed, which is based on six NMR-based lipoprotein
variables [15]. LP-IR scores are closely related to glucose
disposal measured with the hyperinsulinemic-euglycemic
clamp technique and are strongly correlated with home-
ostasis model assessment of insulin resistance (HOMA-IR)
[15, 16]. Both the LP-IR and the plasma total BCAA
concentration have been found to predict incident T2D in
several population studies [16–20].
In the absence of data concerning effects of PA treatment
on NMR-derived biomarkers, the present study was initi-
ated to test the effects of unilateral ADX in APA patients on
plasma lipoprotein subfractions, LP-IR, BCAA, and GlycA.
Materials and methods
Study population
The diagnostic work-up of the study participants was per-
formed in accordance with the Endocrine Society Practice
Guidelines [21]. Patients suspected for PA were screened
using aldosterone-to-renin ratio (ARR; cut-off 12.0 ng/mU,
sitting position). If elevated, antihypertensive medication
was stopped for at least 1 week (e.g., angiotensin-
converting enzyme inhibitors, beta blockers, calcium
antagonists, and low-dose thiazides) and 4 weeks (e.g.,
mineralocorticoid antagonists) whenever possible, other-
wise patients received drugs with minimal effect on the
ARR, such as alpha-receptor (doxazosin) or calcium-
channel blockers (verapamil). Thereafter all subjects were
retested again. If ARR remained abnormal, confirmatory
testing (e.g., sodium loading test, captopril challenge test)
was performed. In case of confirmed diagnosis of PA,
adrenal vein sampling was used for subtype differentiation
between unilateral and bilateral disease. Abstaining from
ACTH infusion, selectivity of the catheter was assumed if
the cortisol concentration (using rapid intra-procedure cor-
tisol measurement) within the adrenal vein was at least two
times higher than that in the simultaneously drawn periph-
eral sample. The diagnosis of unilateral disease was made if
the aldosterone-to-cortisol ratio (A/C-ratio) of one adrenal
vein was at least four times higher than the A/C-ratio of the
contralateral side [22, 23].
For the present analysis we selected 19 patients from the
Munich center of the German Conn’s Registry–Else
Kröner-Fresenius Hyperaldosteronism registry fulfilling the
following criteria: (1) confirmed unilateral PA treated by
ADX; (2) no evidence of postoperative adrenal insuffi-
ciency at 6-month follow-up according to ACTH stimula-
tion testing; and (3) no evidence of T2D at baseline (defined
as a FPG ≥ 126 mg/dl, a HbA1c value ≥6.5% (≥48 mmol/
mol) or use of glucose lowering drugs) or other relevant
metabolic disorders or treatment with lipid-lowering drugs.
All patients were studied after an overnight fast and were re-
evaluated 6 months after surgical treatment in a standar-
dized fashion.
Blood samples were taken between 8:00 and 10:00 A.M.
On each occasion, the evaluation included the collection of
anthropometric data and clinical characteristics such as
duration of hypertension and current medication. Blood
pressure was obtained in the sitting position after at least
15 min of rest in our outpatient clinic. 24-h ambulatory
blood pressure measurements were also performed before
and after PA treatment. HOMA-IR was calculated as fol-
lows: (insulin fasting [μU/ml] × FPG [mg/dl])/405.
All patients gave written informed consent and the ethics
committees of the University of Munich approved the
protocol.
Laboratory methods
Laboratory work-up was performed immediately after the
withdrawal of blood samples, in a fasting state in sitting
position. Plasma aldosterone concentration and active renin
concentration were measured using the Liaison chemilu-
minescence assay (Diasorin) and routine parameters using
standard methods in our central laboratory [11]. Creatinine,
glucose, and HbA1c were measured using routine methods
[11]. Estimated glomerular filtration rate (eGFR) was cal-
culated using the Modification of Diet in Renal Disease
formula. Blood samples for NMR analysis were prepared by
centrifugation at 1400 × g for 15 min, stored at −80 °C and
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sent frozen to LabCorp, Morrisville, NC, USA. NMR
spectra were acquired on Vantera® Clinical Analyzers from
ethylene diamine tetra acetic acid plasma samples at Lab-
Corp as described in [16]. The NMR MetaboProfile analy-
sis, which reports concentrations of lipids, apolipoproteins,
lipoprotein particles and sizes, and BCAA, was performed
using a recently developed deconvolution algorithm
[15, 16]. Linear regression of the lipoprotein subclass signal
areas against serum lipid and chemically measured apoli-
poprotein levels in a large study population provided the
conversion factors to generate concentrations of total cho-
lesterol (TC), TG, low-density lipoprotein cholesterol
(LDL-C) and high-density lipoprotein cholesterol (HDL-C),
apoB and apolipoprotein A-I. The inter-assay precision for
these parameters ranges from 1.4 to 6.2%. The diameters for
the lipoprotein classes reported by the LP4 algorithm are
TRL particles (TRL-P) (24–240 nm) (subdivided into very
large, large, medium, small and very small TRL-P), LDL
particles (LDL-P) (19–23 nm) (subdivided into large,
medium and small LDL-P), and HDL particles (HDL-P)
(7.4–12.0 nm) (subdivided into large, medium and small
HDL-P). Inter-assay precision for TRL-P, LDL-P, and
HDL-P are 6.4%, 1.5%, and 2.4%, respectively. Mean TRL,
LDL, and HDL particle sizes are weighted averages derived
from the sum of the diameter of each subclass multiplied by
its relative mass percentage. The LP-IR score was calcu-
lated using six NMR-measured lipoprotein variables:
weighted average sizes of TRL, LDL, and HDL, combined
with concentrations of large TRL-P, small LDL-P and large
HDL-P [15]. LP-IR scores vary between 0 and 100; the
higher the score the more insulin resistant the individual
[15, 16]. Details for the quantification of the BCAA have
been reported previously [19]. The inter-assay precisions
are 3.1% for valine, 5.9% for leucine 14.1% for isoleucine,
and 3.2% for total BCAA. The GlycA signal was quantified
as described in [24, 25]. The GlycA NMR signal originates
from highly mobile protons of N-acetylglucosamine resi-
dues located on the carbohydrate side-chains of circulating
acute phase proteins (e.g., α1-acid glycoprotein, haptoglo-
bin, α1-antitrypsin, α1-antichymotrypsin, and transferrin).
The signals from these N-acetylglucosamine residues were
used to calculate the concentrations of GlycA (µmol/L). The
intra-assay and inter-assay precisions for GlycA are 1.9%
and 2.6%, respectively.
Statistical analysis
Data analysis was performed using IBM SPSS software
(version 25.0, SPSS Inc., USA). Results are given in
median and 25th and 75th percentile if not mentioned
otherwise. body mass index (BMI) was calculated as
weight in kilograms divided by the square of the height in
meters. Comparisons in variables before and after ADX
were performed using Wilcoxon singed-rank test tests for
paired observations. Spearman’s Rank Order test was used
to determine the relationships between variables. Two-
sided p values < 0.05 were considered to be statistically
significant.
Results
Ten men and nine women participated (median age 46
years). All had at baseline high aldosterone levels and ele-
vated blood pressure, as expected. Adrenal-venous sam-
pling pointed to unilateral disease in all of them, with a right
sided APA in ten and a left sided APA in nine patients.
Imaging techniques confirmed the lateralization results in
10 of 19 cases. There was only one patient with con-
tralateral mass as well as eight patients without any adrenal
mass detected by imaging. Adrenal mass size was in median
10 mm and ranged from 2 to 22 mm.
Parameters of renal function as well as FPG and other
parameters of glucose metabolism were within normal
ranges (Table 1). With a median BMI of 25.6 kg/m2 patients
were slightly overweight (Table 1). Six patients had a his-
tory of nicotine use whereas three of them were current
smokers. Twelve patients consumed moderate amounts of
alcohol while seven patients were abstainers.
Six months after unilateral ADX, aldosterone and renin
levels were normalized (Table 1). Outpatient clinic systolic
and diastolic blood pressure did not change significantly,
but defined daily doses of antihypertensives as well as
ambulatory 24-h systolic and diastolic blood pressure had
reduced significantly. Expectedly, eGFR was reduced,
consequent to reduced renal plasma flow after PA treatment
(Table 1). BMI and FPG remained unaltered but HbA1c
increased slightly after ADX. Postoperative plasma insulin
levels were not available. Plasma TC and LDL-C were
unchanged, whereas apoB levels tended to increase. Plasma
TG increased, coinciding with an increase in TRL choles-
terol. This increase in TG was attributable to an increase in
large TRL-P and resulted in an increase in TRL size
(Table 2). Although HDL-C and HDL-P did not change,
small HDL-P increased, resulting in a decrease in HDL size
(Table 2). Consequent to these changes in TRL and HDL
subfractions, LP-IR scores increased (Table 2). This
increase in LP-IR tended to be correlated with the increase
in HbA1c (r= 0.352, p= 0.14) and was significantly cor-
related with the decrease in eGFR (r=−0.466, p= 0.044).
In addition, we observed a positive correlation of LP-IR
scores with HOMA-IR at baseline (r= 0.543, p= 0.016).
Of further note, plasma total BCAA increased after
ADX, mainly due to increases in valine and isoleucine. This
increase in total BCAA was not significantly related to the
decrease in eGFR (r= 0.144, p= 0.556) or the increase in
Endocrine
LP-IR scores (r= 0.322, p= 0.178). Plasma GlycA did not
change after ADX (Table 2).
Discussion
In this preliminary study, we present for the first time results
of NMR-measured lipoprotein subfractions and other tar-
geted metabolomics biomarkers before and after unilateral
ADX for APA. First, the current study shows that plasma
TG are increased after ADX consequent to a rise in large
TRLs. As a result, TRL size increased, and these changes
were accompanied by a shift in HDL particle distribution
with an increase in small HDL-P and a decrease in HDL
particle size. Consequently, the LP-IR score, an NMR-
based measure of insulin resistance, increased. Of further
note, we observed a hitherto unreported rise in total plasma
BCAA after ADX. Given that the LP-IR scores [16–18] and
BCAA concentrations [20] have been shown to predict
incident diabetes in population-based cohort studies, our
present findings suggest that the risk of future diabetes
development is not ameliorated and could even be worsened
in PA patients without T2D initially despite remission of
hyperaldosteronism after unilateral ADX.
The current results regarding the increase in plasma TG
after ADX agree with and expand on previous publications
showing an increase in TG after PA treatment [10–12]. In
comparison, HDL-C tended to decrease, irrespective of the
presence of dyslipidemia before surgery in a Japanese study
[10]. We documented a drop in HDL-C 1 year after uni-
lateral ADX in our earlier German study [11]. In the latter
report, similar lipoprotein changes were observed in patients
with BAH after mineralocorticoid receptor antagonist
(MRA) treatment [11]. A recent study from the German
Conn registry also reported a decrease in HDL-C after
unilateral ADX [5]. In the present study, HDL-C and HDL-
P remained unchanged but HDL size was decreased coin-
ciding with an increase in large TRLs, which is conceivably
attributable at least in part to effects of TRLs on HDL
metabolism via the cholesteryl ester transfer process [26].
We did not observe significant increases in LDL-C and
LDL-P after ADX, but the trends observed were compar-
able with those in the Japanese study which showed an
increase in LDL-C after PA treatment [10]. The mechan-
isms responsible for plasma TRL increments after ADX for
PA are not completely understood. In the previous reports,
the development of dyslipidemia and changes in TG and
HDL-C were found to be dependent on (changes) eGFR
Table 1 Clinical characteristics,
plasma aldosterone, renin,
potassium, and renal function in
19 patients with primary
aldosteronism due to unilateral
aldosterone-producing adenoma
Patient characteristics (n= 19) n Before ADX After ADX p value
Gender [f/m] 19 9/10 –
Age [years] 19 46 [41; 56] –
Adrenal mass size [mm] 11 10 [8; 19] –
BMI [kg/m2] 19 25.6 [23.8; 29.4] 26.2 [23.8; 30.7] 0.583
Aldosterone [ng/l] 19 189 [129; 270] 71[49; 115] 0.000
Plasma renin [mU/l] 19 4.0 [2.0; 6.5] 8.6 [6.2; 14,8] 0.001
SBP [mmHg] 19 153 [131; 167] 140 [129; 155] 0.126
DBP [mmHg] 19 91 [83; 97] 96 [87; 102] 0.268
24-h SBP [mmHg] 12 153 [148; 158] 127 [119; 132] 0.018
24-h DBP [mmHg] 12 98 [93; 105] 79 [74; 86] 0.018
DDD of antihypertensive medication [n] 19 2.0 [1.3; 3.0] 0.0 [0.0; 0.5] 0.002
Serum potassium [mmol/l] 19 3.5 [3.3; 3.9] 4.2 [4.0; 4.3] 0.000
Serum creatinine [mg/dl] 19 0.9 [0.8; 1.0] 0.9 [0.8; 1.0] 0.029
eGFR [ml/min/1.73 m2] 19 81 [75; 93] 77 [65; 94] 0.013
FPG [mg/dl] 19 97 [91; 102] 96 [89; 103] 0.678
Insulin [μU/ml] 19 5.6 [4.2; 11.5] n.a.
HOMA-IR [µU/ml × FPG [mg/dl])/405] 19 1.2 [0.9; 2.4] n.a.
HbA1c [%] 19 5.1 [5.0; 5.5] 5.4 [5.2; 5.7] 0.002
Data before and 6 months after adrenalectomy are shown
Continuous data are given as median (interquartile) range
Comparisons were performed by Wilcoxon signed rank tests. Statistically significant changes are marked in
bold. To convert creatinine from mg/dl to µmol/l multiply by 88.4. To convert glucose from mg/dl to mmol/l
multiply by 0.056. To convert HbA1c from % to mmol/mol multiply by 8.5
ADX adrenalectomy, DDD defined daily dose, DBP diastolic blood pressure, eGFR estimated glomerular
filtration rate, FPG fasting plasma glucose, n.a. not available, SBP systolic blood pressure
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after treatment [10, 11]. In line, we observed that changes in
LP-IR scores were correlated with changes in eGFR.
However, the decline in eGFR after ADX as observed in the
current study was modest, amounting to about 5%, which
makes a contribution of a decline in kidney function on
plasma lipoprotein alterations uncertain. Moreover, HDL-C
is inversely rather than directly correlated with eGFR in
subjects without chronic kidney disease [27], questioning
whether such a limited decline in kidney function may
explain a decrease in HDL-C after ADX. Of further rele-
vance, co-secretion of cortisol in PA and relative adrenal
insufficiency may affect glucose and lipid metabolism after
ADX [5]. Notably, in all the cases included in the present
series, adrenal function had recovered 6 months after ADX.
Finally, it should be appreciated that the present study was
carried out along with routine clinical treatment for PA due
to APA. As a consequence, antihypertensive treatment
was extensively reduced after surgery. Hence, we cannot
Table 2 Plasma glucose, lipids, apolipoproteins, lipoprotein subfractions, lipoprotein sizes, the Lipoprotein insulin resistance (LP-IR) score,
branched-chain amino acids (BCAA), and GlycA in 19 patients with primary aldosteronism due to unilateral aldosterone-producing adenoma
Patient characteristics (n= 19) Before ADX After ADX p value
Total cholesterol [mg/dl] 158 [146; 169] 169 [151; 187] 0.142
HDL-C [mg/dl] 49 [42; 66] 45 [41; 61] 0.355
LDL-C [mg/dl] 87 [67; 105] 99 [69; 112] 0.456
Triglycerides [mg/dl] 84 [73; 106] 108 [87; 133] 0.004
TRL-TG [mg/dl] 45 [42; 63] 66 [57; 90] 0.009
TRL-C [mg/dl] 19 [16; 23] 25 [18; 33] 0.040
ApoB [mg/dl] 76 [59; 85] 89 [59; 98] 0.098
ApoA-I [mg/dl] 129 [116; 146] 127 [119; 147] 0.896
TRL-P [nmol/l] 122 [84; 149] 124 [105; 192] 0.136
Very large TRL-P [nmol/l] 0.0 [0.0; 0.1] 0.0 [0.0; 0.1] 0.227
Large TRL-P [nmol/l] 1.0 [0.0; 3.6] 2.8 [1.6; 5.4] 0.007
Medium TRL-P [nmol/l] 6.0 [3.7; 9.5] 9.9 [3.7; 17.0] 0.077
Small TRL-P [nmol/l] 34 [21; 48] 29.8 [8.5; 78.3] 0.904
Very small TRL-P [nmol/l] 78 [29; 100] 77.9 [35.5; 126.8] 0.546
LDL- P [nmol/l] 1246 [955; 1490] 1473 [991; 1625] 0.153
Large LDL-P [nmol/l] 510 [419; 706] 457 [364; 570] 0.094
Medium-LDL-P [nmol/l] 269 [88; 560] 232 [0; 466] 0.546
Small LDL-P [nmol/l] 412 [194; 511] 389 [222; 807] 0.212
HDL-P [µmol/l] 20 [18; 22] 21 [18; 23] 0.231
Large HDL-P [µmol/l] 2.2 [0.9; 3.1] 1.5 [0.9; 3.4] 0.323
Medium HDL-P [µmol/l] 5.1 [3.7; 6.6] 4.8 [3.9; 6.0] 0.235
Small HDL-P [µmol/l] 12.4 [11.3; 14.3] 14.4 [12.3; 15.7] 0.038
TRL size [nm] 43.4 [39.6; 53.4] 48.1 [42.2; 61.4] 0.027
LDL size [nm] 21.4 [21.3; 21.7] 21.4 [21.1; 21.7] 0.346
HDL size [nm] 9.1 [8.8; 9.7] 8.9 [8.5; 9.3] 0.015
LP-IR score 30 [15; 51] 54 [20; 63] 0.001
Total BCAA [µmol/l] 334 [277; 374] 386 [299; 447] 0.017
Valine [µmol/l] 187 [177; 195] 209 [171; 232] 0.016
Leucine [µmol/l] 100 [76; 114] 116 [79; 135] 0.117
Isoleucine [µmol/l] 49 [35; 60] 55 [40; 68] 0.011
GlycA [µmol/l] 329 [279; 367] 333 [301; 378] 0.587
Data before and 6 months after adrenalectomy are shown
Continuous data are given as median (interquartile) range
Comparisons were performed by Wilcoxon signed rank tests. Statistically significant changes are marked in bold. To convert cholesterol form mg/
dl to mmol/l multiply by 0.02586. To convert triglycerides from mg/dl to mmol/l multiply by 0.01129
ADX adrenalectomy, Apo apolipoprotein, BCAA branched-chain amino acids, HDL high-density lipoproteins, HDL-P HDL particles, LDL low-
density lipoproteins, LDL-C LDL cholesterol, LDL-P LDL particles, TRL triglyceride-rich lipoproteins, TRL-P TRL particles
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exclude that cessation of certain drugs like MRA or dox-
azosin could have influenced lipid metabolism [28–30].
Yet, we found that MRA in case of bilateral disease elicits
comparable changes in TG and HDL-C compared with
ADX for APA [11].
The LP-IR signature reflects the multifaceted aspects
of insulin resistance on lipoprotein metabolism [18]. The
LP-IR index is robustly correlated with HOMA-IR [16], a
finding which was reinforced in APA patients. Despite its
strong relationship with HOMA-IR [16, 17], LP-IR
scores predicted incident T2D even when taking
account of HOMA-IR [16, 17]. Notably, LP-IR improves
diabetes risk classification beyond the Framingham Off-
spring risk score [16, 17], and it has been proposed that
LP-IR may reflect early insulin resistant dyslipidemia
before development of hyperglycemia [18]. Hence, it
could be proposed that the higher LP-IR scores after
ADX represents an early marker of elevated diabetes risk
before a rise in FPG becomes evident. Accumulating
evidence supports the idea that BCAA are important in
the pathogenesis of dysglycemia [31]. BCAA may disrupt
the function of the mammalian target of rapamycin
complex 1, which subsequently leads to insulin resistance
and oxidative stress [32, 33]. In view of the recent find-
ings demonstrating that plasma BCAA predicts new onset
T2D [19] we surmise that higher total BCAA could
translate into increased diabetes risk after ADX. Taken
together, we postulate that two, at least in part, inde-
pendent pathways are operating that could pose patients
with biochemical remission of PA at increased risk for
diabetes development after ADX.
Finally, we did not observe that GlycA decreased after
ADX. This result suggests that low-grade systemic inflam-
mation is unaffected by ADX, and is unexpected in view of
the recent results showing higher GlycA levels in untreated
PA patients compared with healthy subjects and subjects
with (un)treated hypertension [7].
The current study was conducted in a limited number of
patients, we consider the present findings preliminary.
Moreover, we did not follow adrenal incidentaloma patients
without evidence of hormonal hypersecretion as a control
group to determine variations in NMR-derived biomarkers
over time. However, our prospective observations in a
rather homogeneous group of PA patients whose hyper-
aldosteronism was remitted biochemically after ADX can
be seen as a strength of the present study. Nonetheless, it is
evident that longitudinal studies with prolonged follow-up
in larger patient groups are required to determine whether
the long-term risk of new onset T2D is indeed elevated in
this patient category.
In conclusion, based on an increase in both the LP-IR
index and BCAA, our current findings suggest that diabetes
risk is not improved but may even be increased after ADX
for APA despite remission of PA in patients without T2D
initially.
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